Compugen Ltd. CGEN
2.09 USD -0.05 (-2.34%)
At closeNov 10, 2026, 4:00 PM EST
2.09 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
2.03 Day range 2.14
1.43 52-week range 3.24
- YTD
- +36.60%
- 1 year
- +25.15%
News
seekingalpha.com Compugen: COM701 Data On Track And Continued Bispecific Rilvegostomig Development Compugen Ltd. maintains a "Buy" rating, driven by advancing clinical programs and strong partnership with AstraZeneca for rilvegostomig. The company's lead asset, COM701, is on track for phase 1/2…
prnewswire.com Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI,…
seekingalpha.com Compugen Ltd. (CGEN) Q3 2026 Earnings Call Transcript Compugen Ltd. (CGEN) Q3 2026 Earnings Call Transcript
marketbeat.com What Compugen (CGEN) Said on Its Q3 Earnings Call Compugen NASDAQ: CGEN has completed enrollment in a randomized trial of its ovarian cancer treatment candidate COM701 and expects to report results by the end of the first quarter of 2027, executives…
zacks.com Compugen (CGEN) Reports Q3 Loss, Beats Revenue Estimates Compugen (CGEN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
benzinga.com Compugen Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $3.821M Beat $1.700M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 14.29 percent increase over losses of $(0.07) per…
prnewswire.com Compugen Reports Third Quarter 2026 Results MAIA-ovarian fully enrolled; results expected by end of Q1 2027 Phase 3 rilvegostomig high-level results from partner AstraZeneca anticipated in H2 2027 from ARTEMIDE-Biliary01 trial UnigenX™…
benzinga.com HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.